FHTX Stock FHTX is expected to report earnings to fall -8.33% to -62 cents per share on May 06

A.I.dvisor
at Tickeron.com
05/05/24
Loading...
FHTX - Foghorn Therapeutics
Foghorn Therapeutics Earnings Graph
Q1'24
Est.
$-0.62
Q4'23
Beat
by $0.17
Q3'23
Beat
by $0.36
Q2'23
Beat
by $0.01
Q1'23
Est.
$-0.73
The last earnings report on December 31 showed earnings per share of -57 cents, beating the estimate of -74 cents. P/B Ratio (0.000) is normal, around the industry mean (10.284). P/E Ratio (0.000) is within average values for comparable stocks, (116.129). FHTX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.466). FHTX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.015). P/S Ratio (7.364) is also within normal values, averaging (233.049). With 48.32K shares outstanding, the current market capitalization sits at 254.97M.
View a ticker or compare two or three
FHTXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
500 Technology Square
Phone
+1 617 586-3100
Employees
116
Web
https://www.foghorntx.com